{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:03:57Z","timestamp":1791918237718,"version":"4.3.4"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T00:00:00Z","timestamp":1331856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/nrmicro2745","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T04:46:47Z","timestamp":1331873207000},"page":"243-254","source":"Crossref","is-referenced-by-count":492,"title":["Modulating immunity as a therapy for bacterial infections"],"prefix":"10.1038","volume":"10","author":[{"given":"Robert E. W.","family":"Hancock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Nijnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana J.","family":"Philpott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,16]]},"reference":[{"key":"BFnrmicro2745_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/sj.icb.7100062","volume":"85","author":"IA Clark","year":"2007","unstructured":"Clark, I. A. The advent of the cytokine storm. Immunol. Cell Biol. 85, 271\u2013273 (2007).","journal-title":"Immunol. Cell Biol."},{"key":"BFnrmicro2745_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nri1396","volume":"4","author":"RJ Ulevitch","year":"2004","unstructured":"Ulevitch, R. J. Therapeutics targeting the innate immune system. Nature Rev. Immunol. 4, 512\u2013520 (2004).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrmicro2745_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.copbio.2008.10.006","volume":"19","author":"P Hamill","year":"2008","unstructured":"Hamill, P., Brown, K., Jenssen, H. & Hancock, R. E. Novel anti-infectives: is host defence the answer? Curr. Opin. Biotechnol. 19, 628\u2013636 (2008).","journal-title":"Curr. Opin. Biotechnol."},{"key":"BFnrmicro2745_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.antiviral.2009.10.023","volume":"85","author":"YF Yang","year":"2010","unstructured":"Yang, Y. F. et al. Long-term efficacy of interferon \u03b1 therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Antiviral Res. 85, 361\u2013365 (2010).","journal-title":"Antiviral Res."},{"key":"BFnrmicro2745_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd3365","volume":"10","author":"XR Jiang","year":"2011","unstructured":"Jiang, X. R. et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nature Rev. Drug Discov. 10, 101\u2013111 (2011).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro2745_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/bmb\/62.1.187","volume":"62","author":"A Scherer","year":"2002","unstructured":"Scherer, A. & McLean, A. Mathematical models of vaccination. Br. Med. Bull. 62, 187\u2013199 (2002).","journal-title":"Br. Med. Bull."},{"key":"BFnrmicro2745_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","volume":"124","author":"M Karin","year":"2006","unstructured":"Karin, M., Lawrence, T. & Nizet, V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823\u2013835 (2006).","journal-title":"Cell"},{"key":"BFnrmicro2745_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389\u2013395 (2002).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd3591","volume":"11","author":"CD Fjell","year":"2011","unstructured":"Fjell, C. D., Hiss, J. A., Hancock, R. E. W. & Schneider, G. Designing antimicrobial peptides: form follows function. Nature Rev Drug Discov 11, 37\u201351 (2011).","journal-title":"Nature Rev Drug Discov"},{"key":"BFnrmicro2745_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nri2038","volume":"7","author":"G Trinchieri","year":"2007","unstructured":"Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nature Rev. Immunol. 7, 179\u2013190 (2007).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrmicro2745_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/41131","volume":"388","author":"R Medzhitov","year":"1997","unstructured":"Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394\u2013397 (1997).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR12","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","volume":"282","author":"A Poltorak","year":"1998","unstructured":"Poltorak, A. et al. Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085\u20132088 (1998).","journal-title":"Science"},{"key":"BFnrmicro2745_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2119\/2007-00135.Ferwerda","volume":"14","author":"B Ferwerda","year":"2008","unstructured":"Ferwerda, B. et al. Functional consequences of Toll-like receptor 4 polymorphisms. Mol. Med. 14, 346\u2013352 (2008).","journal-title":"Mol. Med."},{"key":"BFnrmicro2745_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","volume":"9","author":"EJ Hennessy","year":"2010","unstructured":"Hennessy, E. J., Parker, A. E. & O'Neill, L. A. Targeting Toll-like receptors: emerging therapeutics? Nature Rev. Drug Discov. 9, 293\u2013307 (2010). A highly comprehensive review of the ongoing development of TLR agonists and antagonists for therapeutic applications.","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro2745_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/infdis\/167.2.401","volume":"167","author":"SA Zaheer","year":"1993","unstructured":"Zaheer, S. A. et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167, 401\u2013410 (1993).","journal-title":"J. Infect. Dis."},{"key":"BFnrmicro2745_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1196\/annals.1348.030","volume":"1082","author":"DM Klinman","year":"2006","unstructured":"Klinman, D. M., Xie, H. & Ivins, B. E. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann. NY Acad. Sci. 1082, 137\u2013150 (2006).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrmicro2745_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/14728210903146882","volume":"14","author":"L Pastorelli","year":"2009","unstructured":"Pastorelli, L., Pizarro, T. T., Cominelli, F. & Vecchi, M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin. Emerg. Drugs 14, 505\u2013521 (2009).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"BFnrmicro2745_CR18","first-page":"353","volume":"76","author":"A Rozy","year":"2008","unstructured":"Rozy, A. & Chorostowska-Wynimko, J. Bacterial immunostimulants \u2014 mechanism of action and clinical application in respiratory diseases. Pneumonol. Alergol. Pol. 76, 353\u2013359 (2008).","journal-title":"Pneumonol. Alergol. Pol."},{"key":"BFnrmicro2745_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF02850109","volume":"18","author":"SB Ruah","year":"2001","unstructured":"Ruah, S. B., Ruah, C., van Aubel, A., Abel, S. & Elsasser, U. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv. Ther. 18, 151\u2013162 (2001).","journal-title":"Adv. Ther."},{"key":"BFnrmicro2745_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.mib.2003.09.007","volume":"6","author":"U Dittmer","year":"2003","unstructured":"Dittmer, U. & Olbrich, A. R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr. Opin. Microbiol. 6, 472\u2013477 (2003).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnrmicro2745_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1165\/rcmb.2008-0260OC","volume":"42","author":"SE Evans","year":"2009","unstructured":"Evans, S. E. et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am. J. Respir. Cell Mol. Biol. 42, 40\u201350 (2009).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"BFnrmicro2745_CR22","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1128\/IAI.00224-10","volume":"78","author":"N Munoz","year":"2010","unstructured":"Munoz, N. et al. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect. Immun. 78, 4226\u20134233 (2010).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4049\/jimmunol.1000509","volume":"185","author":"FS Yu","year":"2010","unstructured":"Yu, F. S. et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J. Immunol. 185, 1142\u20131149 (2010).","journal-title":"J. Immunol."},{"key":"BFnrmicro2745_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1086\/650203","volume":"201","author":"MA Kinnebrew","year":"2010","unstructured":"Kinnebrew, M. A. et al. Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J. Infect. Dis. 201, 534\u2013543 (2010).","journal-title":"J. Infect. Dis."},{"key":"BFnrmicro2745_CR25","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1164\/rccm.200607-1038OC","volume":"177","author":"CG Clement","year":"2008","unstructured":"Clement, C. G. et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177, 1322\u20131330 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrmicro2745_CR26","doi-asserted-by":"publisher","first-page":"e1000921","DOI":"10.1371\/journal.ppat.1000921","volume":"6","author":"R Ireland","year":"2010","unstructured":"Ireland, R. et al. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog. 6, e1000921 (2010).","journal-title":"PLoS Pathog."},{"key":"BFnrmicro2745_CR27","doi-asserted-by":"publisher","first-page":"e4176","DOI":"10.1371\/journal.pone.0004176","volume":"4","author":"MJ Tuvim","year":"2009","unstructured":"Tuvim, M. J., Evans, S. E., Clement, C. G., Dickey, B. F. & Gilbert, B. E. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 4, e4176 (2009).","journal-title":"PLoS ONE"},{"key":"BFnrmicro2745_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1743-422X-8-97","volume":"8","author":"K Shinya","year":"2011","unstructured":"Shinya, K. et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol. J. 8, 97 (2011).","journal-title":"Virol. J."},{"key":"BFnrmicro2745_CR29","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1172\/JCI40817","volume":"120","author":"LR Antonelli","year":"2010","unstructured":"Antonelli, L. R. et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte\/macrophage population. J. Clin. Invest. 120, 1674\u20131682 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrmicro2745_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMra021333","volume":"348","author":"RS Hotchkiss","year":"2003","unstructured":"Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138\u2013150 (2003). An overview of the complex immune-mediated pathophysiology of sepsis and the complexities of treating patients with sepsis using immunomodulatory therapies.","journal-title":"N. Engl. J. Med."},{"key":"BFnrmicro2745_CR31","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","volume":"38","author":"TW Rice","year":"2010","unstructured":"Rice, T. W. et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38, 1685\u20131694 (2010).","journal-title":"Crit. Care Med."},{"key":"BFnrmicro2745_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/CCM.0b013e3181b07b78","volume":"38","author":"M Tidswell","year":"2010","unstructured":"Tidswell, M. et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38, 72\u201383 (2010).","journal-title":"Crit. Care Med."},{"key":"BFnrmicro2745_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425255.2011.558190","volume":"7","author":"A Barochia","year":"2011","unstructured":"Barochia, A., Solomon, S., Cui, X., Natanson, C. & Eichacker, P. Q. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin. Drug Metab. Toxicol. 7, 479\u2013494 (2011).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnrmicro2745_CR34","doi-asserted-by":"publisher","first-page":"G1167","DOI":"10.1152\/ajpgi.90496.2008","volume":"296","author":"R Ungaro","year":"2009","unstructured":"Ungaro, R. et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1167\u2013G1179 (2009).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"BFnrmicro2745_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cell.2004.07.002","volume":"118","author":"S Rakoff-Nahoum","year":"2004","unstructured":"Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118, 229\u2013241 (2004).","journal-title":"Cell"},{"key":"BFnrmicro2745_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nri2707","volume":"10","author":"MT Abreu","year":"2010","unstructured":"Abreu, M. T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nature Rev. Immunol. 10, 131\u2013144 (2010).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrmicro2745_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2010.02.012","volume":"32","author":"J Dupaul-Chicoine","year":"2010","unstructured":"Dupaul-Chicoine, J. et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32, 367\u2013378 (2010).","journal-title":"Immunity"},{"key":"BFnrmicro2745_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature05590","volume":"446","author":"C Zaph","year":"2007","unstructured":"Zaph, C. et al. Epithelial-cell-intrinsic IKK-\u03b2 expression regulates intestinal immune homeostasis. Nature 446, 552\u2013556 (2007).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1189\/jlb.0411183","volume":"90","author":"C Werts","year":"2011","unstructured":"Werts, C., Rubino, S., Ling, A., Girardin, S. E. & Philpott, D. J. Nod-like receptors in intestinal homeostasis, inflammation, and cancer. J. Leukoc. Biol. 90, 471\u2013482 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrmicro2745_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1600-065X.2011.01047.x","volume":"243","author":"M Sorbara","year":"2011","unstructured":"Sorbara, M. & Philpott, D. Peptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis. Immunol. Rev. 243, 40\u201360 (2011). A review of how peptidoglycan recognition shapes the mammalian immune response.","journal-title":"Immunol. Rev."},{"key":"BFnrmicro2745_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2011.01043.x","volume":"243","author":"JC Leemans","year":"2011","unstructured":"Leemans, J. C., Cassel, S. L. & Sutterwala, F. S. Sensing damage by the NLRP3 inflammasome. Immunol. Rev. 243, 152\u2013162 (2011).","journal-title":"Immunol. Rev."},{"key":"BFnrmicro2745_CR42","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/eji.200940039","volume":"40","author":"R Spreafico","year":"2010","unstructured":"Spreafico, R., Ricciardi-Castagnoli, P. & Mortellaro, A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol. 40, 638\u2013642 (2010).","journal-title":"Eur. J. Immunol."},{"key":"BFnrmicro2745_CR43","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1074\/jbc.C200651200","volume":"278","author":"SE Girardin","year":"2003","unstructured":"Girardin, S. E. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869\u20138872 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrmicro2745_CR44","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1074\/jbc.C200673200","volume":"278","author":"N Inohara","year":"2003","unstructured":"Inohara, N. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278, 5509\u20135512 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrmicro2745_CR45","first-page":"63","volume":"25","author":"L Chedid","year":"1978","unstructured":"Chedid, L., Audibert, F. & Johnson, A. G. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog. Allergy 25, 63\u2013105 (1978).","journal-title":"Prog. Allergy"},{"key":"BFnrmicro2745_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.immuni.2007.03.009","volume":"26","author":"JH Fritz","year":"2007","unstructured":"Fritz, J. H., et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26, 445\u2013459 (2007).","journal-title":"Immunity"},{"key":"BFnrmicro2745_CR47","doi-asserted-by":"publisher","first-page":"14896","DOI":"10.1073\/pnas.1015063108","volume":"108","author":"JG Magalhaes","year":"2011","unstructured":"Magalhaes, J. G. et al. Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation. Proc. Natl Acad. Sci. USA 108, 14896\u201314901 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro2745_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.drudis.2009.02.009","volume":"14","author":"DT O'Hagan","year":"2009","unstructured":"O'Hagan, D. T. & De Gregorio, E. The path to a successful vaccine adjuvant \u2013 'the long and winding road'. Drug Discov. Today 14, 541\u2013551 (2009).","journal-title":"Drug Discov. Today"},{"key":"BFnrmicro2745_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/dkg063","volume":"51","author":"GM Bahr","year":"2003","unstructured":"Bahr, G. M. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. J. Antimicrob. Chemother. 51, 5\u20138 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro2745_CR50","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.7164\/antibiotics.36.1045","volume":"36","author":"Y Mine","year":"1983","unstructured":"Mine, Y. et al. Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice. J. Antibiot. (Tokyo) 36, 1045\u20131050 (1983).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFnrmicro2745_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.vaccine.2008.11.017","volume":"27","author":"A Wardowska","year":"2009","unstructured":"Wardowska, A. et al. Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis. Vaccine 27, 369\u2013374 (2009).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd2783","volume":"8","author":"K Geddes","year":"2009","unstructured":"Geddes, K., Magalhaes, J. G. & Girardin, S. E. Unleashing the therapeutic potential of NOD-like receptors. Nature Rev. Drug Discov. 8, 465\u2013479 (2009).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro2745_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0264-410X(95)00236-T","volume":"14","author":"A Fukushima","year":"1996","unstructured":"Fukushima, A. et al. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Vaccine 14, 485\u2013491 (1996).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR54","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.4049\/jimmunol.158.11.5357","volume":"158","author":"K Sarkar","year":"1997","unstructured":"Sarkar, K. & Das, P. K. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. J. Immunol. 158, 5357\u20135365 (1997).","journal-title":"J. Immunol."},{"key":"BFnrmicro2745_CR55","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1128\/IAI.00519-09","volume":"77","author":"L Le Bourhis","year":"2009","unstructured":"Le Bourhis, L. et al. Role of Nod1 in mucosal dendritic cells during Salmonella pathogenicity island 1-independent Salmonella enterica serovar Typhimurium infection. Infect. Immun. 77, 4480\u20134486 (2009).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR56","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/clinids\/14.5.1100","volume":"14","author":"T O'Reilly","year":"1992","unstructured":"O'Reilly, T. & Zak, O. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin. Infect. Dis. 14, 1100\u20131109 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrmicro2745_CR57","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chom.2011.05.006","volume":"9","author":"YG Kim","year":"2011","unstructured":"Kim, Y. G. et al. Viral infection augments Nod1\/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 9, 496\u2013507 (2011).","journal-title":"Cell Host Microbe"},{"key":"BFnrmicro2745_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11010-005-3701-0","volume":"268","author":"GM Argast","year":"2005","unstructured":"Argast, G. M., Fausto, N. & Campbell, J. S. Inhibition of RIP2\/RICK\/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol. Cell. Biochem. 268, 129\u2013140 (2005).","journal-title":"Mol. Cell. Biochem."},{"key":"BFnrmicro2745_CR59","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"RE Hancock","year":"2006","unstructured":"Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotech. 24, 1551\u20131557 (2006).","journal-title":"Nature Biotech."},{"key":"BFnrmicro2745_CR60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/35106587","volume":"414","author":"V Nizet","year":"2001","unstructured":"Nizet, V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454\u2013457 (2001).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR61","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMoa021481","volume":"347","author":"PY Ong","year":"2002","unstructured":"Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151\u20131160 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrmicro2745_CR62","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.4049\/jimmunol.0901491","volume":"183","author":"A Nijnik","year":"2009","unstructured":"Nijnik, A., Pistolic, J., Wyatt, A., Tam, S. & Hancock, R. E. Human cathelicidin peptide LL-37 modulates the effects of IFN-\u03b3 on APCs. J. Immunol. 183, 5788\u20135798 (2009).","journal-title":"J. Immunol."},{"key":"BFnrmicro2745_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nbt1288","volume":"25","author":"MG Scott","year":"2007","unstructured":"Scott, M. G. et al. An anti-infective peptide that selectively modulates the innate immune response. Nature Biotech. 25, 465\u2013472 (2007). A study demonstrating that a synthetic immunomodulatory peptide with no direct antimicrobial activity can offer protection against antibiotic-resistant infections in mouse models, while inhibiting an excessive inflammatory response.","journal-title":"Nature Biotech."},{"key":"BFnrmicro2745_CR64","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/IAI.00318-08","volume":"76","author":"J Overhage","year":"2008","unstructured":"Overhage, J. et al. The human host defence peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 76, 4176\u20134182 (2008).","journal-title":"Infect Immun."},{"key":"BFnrmicro2745_CR65","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/sj.jid.5701043","volume":"128","author":"M Carretero","year":"2008","unstructured":"Carretero, M. et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 128, 223\u2013236 (2008).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrmicro2745_CR66","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/jgm.1287","volume":"11","author":"T Hirsch","year":"2009","unstructured":"Hirsch, T. et al. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J. Gene Med. 11, 220\u2013228 (2009).","journal-title":"J. Gene Med."},{"key":"BFnrmicro2745_CR67","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.tibtech.2009.07.004","volume":"27","author":"DM Easton","year":"2009","unstructured":"Easton, D. M., Nijnik, A., Mayer, M. L. & Hancock, R. E. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 27, 582\u2013590 (2009). A recent comprehensive review of the ongoing development of synthetic peptides as immunomodulatory therapeutics.","journal-title":"Trends Biotechnol."},{"key":"BFnrmicro2745_CR68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbrc.2005.01.093","volume":"329","author":"DK Karaolis","year":"2005","unstructured":"Karaolis, D. K. et al. 3\u2032,5\u2032-cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem. Biophys. Res. Commun. 329, 40\u201345 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrmicro2745_CR69","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1128\/AAC.49.8.3109-3113.2005","volume":"49","author":"E Brouillette","year":"2005","unstructured":"Brouillette, E., Hyodo, M., Hayakawa, Y., Karaolis, D. K. & Malouin, F. 3\u2032,5\u2032-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob. Agents Chemother. 49, 3109\u20133113 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro2745_CR70","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.4049\/jimmunol.178.4.2171","volume":"178","author":"DK Karaolis","year":"2007","unstructured":"Karaolis, D. K. et al. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol. 178, 2171\u20132181 (2007).","journal-title":"J. Immunol."},{"key":"BFnrmicro2745_CR71","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1016\/j.vaccine.2010.02.081","volume":"28","author":"W Chen","year":"2010","unstructured":"Chen, W., Kuolee, R. & Yan, H. The potential of 3\u2032,5\u2032-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine 28, 3080\u20133085 (2010).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR72","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1016\/j.vaccine.2011.05.026","volume":"29","author":"T Ebensen","year":"2011","unstructured":"Ebensen, T. et al. Bis-(3\u2032,5\u2032)-cyclic dimeric adenosine monophosphate: strong Th1\/Th2\/Th17 promoting mucosal adjuvant. Vaccine 29, 5210\u20135220 (2011).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR73","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature10429","volume":"478","author":"DL Burdette","year":"2011","unstructured":"Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515\u2013518 (2011).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR74","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1128\/IAI.00999-10","volume":"79","author":"JD Sauer","year":"2011","unstructured":"Sauer, J. D. et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79, 688\u2013694 (2011).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR75","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1126\/science.1189801","volume":"328","author":"JJ Woodward","year":"2010","unstructured":"Woodward, J. J., Iavarone, A. T. & Portnoy, D. A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 328, 1703\u20131705 (2010).","journal-title":"Science"},{"key":"BFnrmicro2745_CR76","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1121357","volume":"311","author":"A Camilli","year":"2006","unstructured":"Camilli, A. & Bassler, B. L. Bacterial small-molecule signaling pathways. Science 311, 1113\u20131116 (2006).","journal-title":"Science"},{"key":"BFnrmicro2745_CR77","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1128\/jb.184.4.1132-1139.2002","volume":"184","author":"RS Smith","year":"2002","unstructured":"Smith, R. S., Harris, S. G., Phipps, R. & Iglewski, B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)homoserine lactone contributes to virulence and induces inflammation in vivo. J. Bacteriol. 184, 1132\u20131139 (2002).","journal-title":"J. Bacteriol."},{"key":"BFnrmicro2745_CR78","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/cr100045m","volume":"111","author":"M Teplitski","year":"2011","unstructured":"Teplitski, M., Mathesius, U. & Rumbaugh, K. P. Perception and degradation of N-acyl homoserine lactone quorum sensing signals by mammalian and plant cells. Chem. Rev. 111, 100\u2013116 (2011). A thorough overview of the mechanisms of 'cross-kingdom' communication by quorum sensing molecules.","journal-title":"Chem. Rev."},{"key":"BFnrmicro2745_CR79","doi-asserted-by":"publisher","first-page":"e16246","DOI":"10.1371\/journal.pone.0016246","volume":"6","author":"ML Mayer","year":"2011","unstructured":"Mayer, M. L., Sheridan, J. A., Blohmke, C. J., Turvey, S. E. & Hancock, R. E. The Pseudomonas aeruginosa autoinducer 3O-C12 homoserine lactone provokes hyperinflammatory responses from cystic fibrosis airway epithelial cells. PLoS ONE 6, e16246 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrmicro2745_CR80","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1128\/IAI.00096-11","volume":"79","author":"BK Khajanchi","year":"2011","unstructured":"Khajanchi, B. K., Kirtley, M. L., Brackman, S. M. & Chopra, A. K. Immunomodulatory and protective roles of quorum-sensing signaling molecules N-acyl homoserine lactones during infection of mice with Aeromonas hydrophila. Infect. Immun. 79, 2646\u20132657 (2011).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR81","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1021\/jo101237e","volume":"75","author":"ME Mattmann","year":"2010","unstructured":"Mattmann, M. E. & Blackwell, H. E. Small molecules that modulate quorum sensing and control virulence in Pseudomonas aeruginosa. J. Org. Chem. 75, 6737\u20136746 (2010). A discussion about the strategies that can be used to interfere with quorum sensing pathways in Pseudomonas aeruginosa to potentially affect therapies.","journal-title":"J. Org. Chem."},{"key":"BFnrmicro2745_CR82","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1099\/jmm.0.46658-0","volume":"55","author":"S Miyairi","year":"2006","unstructured":"Miyairi, S. et al. Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J. Med. Microbiol. 55, 1381\u20131387 (2006).","journal-title":"J. Med. Microbiol."},{"key":"BFnrmicro2745_CR83","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/jac\/dkh223","volume":"53","author":"H Wu","year":"2004","unstructured":"Wu, H. et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53, 1054\u20131061 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro2745_CR84","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.21193","volume":"45","author":"AR Smyth","year":"2010","unstructured":"Smyth, A. R. et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis\u2014a pilot randomized controlled trial. Pediatr. Pulmonol. 45, 356\u2013362 (2010).","journal-title":"Pediatr. Pulmonol."},{"key":"BFnrmicro2745_CR85","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1128\/AAC.00045-11","volume":"55","author":"G Brackman","year":"2011","unstructured":"Brackman, G., Cos, P., Maes, L., Nelis, H. J. & Coenye, T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob. Agents Chemother. 55, 2655\u20132661 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro2745_CR86","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.it.2009.03.009","volume":"30","author":"JL Gardy","year":"2009","unstructured":"Gardy, J. L., Lynn, D. J., Brinkman, F. S. & Hancock, R. E. Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol. 30, 249\u2013262 (2009). A review of the applications of bioinformatics and systems biology in the study of innate immunity and host\u2013pathogen interactions, including many references to online resources, such as databases and software tools, that are openly available to the scientific community.","journal-title":"Trends Immunol."},{"key":"BFnrmicro2745_CR87","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/nature07830","volume":"458","author":"BS Park","year":"2009","unstructured":"Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4\u2013MD-2 complex. Nature 458, 1191\u20131195 (2009).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR88","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.cell.2007.09.008","volume":"130","author":"MS Jin","year":"2007","unstructured":"Jin, M. S. et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130, 1071\u20131082 (2007).","journal-title":"Cell"},{"key":"BFnrmicro2745_CR89","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1126\/science.1115253","volume":"309","author":"J Choe","year":"2005","unstructured":"Choe, J., Kelker, M. S. & Wilson, I. A. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309, 581\u2013585 (2005).","journal-title":"Science"},{"key":"BFnrmicro2745_CR90","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1126\/science.1135299","volume":"314","author":"AL Gavin","year":"2006","unstructured":"Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936\u20131938 (2006).","journal-title":"Science"},{"key":"BFnrmicro2745_CR91","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543\u2013547 (2011). A recent study demonstrating that ligation of multiple TLRs by vaccine adjuvants is required for induction of long-term antibody responses and immunological memory.","journal-title":"Nature"},{"key":"BFnrmicro2745_CR92","first-page":"505","volume":"5","author":"B Guy","year":"2007","unstructured":"Guy, B. The perfect mix: recent progress in adjuvant research. Nature Rev. Microbiol. 5, 505\u2013517 (2007).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro2745_CR93","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.it.2009.07.009","volume":"30","author":"SK Biswas","year":"2009","unstructured":"Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475\u2013487 (2009).","journal-title":"Trends Immunol."},{"key":"BFnrmicro2745_CR94","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1016\/j.vaccine.2006.03.071","volume":"24","author":"C Schellack","year":"2006","unstructured":"Schellack, C. et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24, 5461\u20135472 (2006).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR95","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","volume":"29","author":"JT van Dissel","year":"2011","unstructured":"van Dissel, J. T. et al. Ag85B\u2013ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29, 2100\u20132109 (2011).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR96","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/nbt1113","volume":"23","author":"K Hilpert","year":"2005","unstructured":"Hilpert, K., Volkmer-Engert, R., Walter, T. & Hancock, R. E. High-throughput generation of small antibacterial peptides with improved activity. Nature Biotech. 23, 1008\u20131012 (2005).","journal-title":"Nature Biotech."},{"key":"BFnrmicro2745_CR97","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/psc.908","volume":"14","author":"H Jenssen","year":"2008","unstructured":"Jenssen, H., Fjell, C. D., Cherkasov, A. & Hancock, R. E. QSAR modeling and computer-aided design of antimicrobial peptides. J. Pept. Sci. 14, 110\u2013114 (2008).","journal-title":"J. Pept. Sci."},{"key":"BFnrmicro2745_CR98","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nature05233","volume":"443","author":"C Loose","year":"2006","unstructured":"Loose, C., Jensen, K., Rigoutsos, I. & Stephanopoulos, G. A linguistic model for the rational design of antimicrobial peptides. Nature 443, 867\u2013869 (2006).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR99","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.4049\/jimmunol.174.7.4271","volume":"174","author":"MH Braff","year":"2005","unstructured":"Braff, M. H. et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174, 4271\u20134278 (2005).","journal-title":"J. Immunol."},{"key":"BFnrmicro2745_CR100","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.4049\/jimmunol.0901813","volume":"184","author":"A Nijnik","year":"2010","unstructured":"Nijnik, A. et al. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol. 184, 2539\u20132550 (2010).","journal-title":"J. Immunol."},{"key":"BFnrmicro2745_CR101","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1389203033487054","volume":"4","author":"PM Fischer","year":"2003","unstructured":"Fischer, P. M. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr. Protein Pept. Sci. 4, 339\u2013356 (2003).","journal-title":"Curr. Protein Pept. Sci."},{"key":"BFnrmicro2745_CR102","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature06116","volume":"449","author":"R Lande","year":"2007","unstructured":"Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564\u2013569 (2007).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR103","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1016\/j.vaccine.2009.05.094","volume":"27","author":"J Kindrachuk","year":"2009","unstructured":"Kindrachuk, J. et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27, 4662\u20134671 (2009).","journal-title":"Vaccine"},{"key":"BFnrmicro2745_CR104","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(10)61889-2","volume":"377","author":"AR Martineau","year":"2011","unstructured":"Martineau, A. R. et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377, 242\u2013250 (2011).","journal-title":"Lancet"},{"key":"BFnrmicro2745_CR105","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"PT Liu","year":"2006","unstructured":"Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770\u20131773 (2006). A study linking vitamin D deficiency to impaired immune defences against tuberculosis in the human population.","journal-title":"Science"},{"key":"BFnrmicro2745_CR106","doi-asserted-by":"publisher","first-page":"9178","DOI":"10.1073\/pnas.0602888103","volume":"103","author":"R Raqib","year":"2006","unstructured":"Raqib, R. et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc. Natl Acad. Sci. USA 103, 9178\u20139183 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro2745_CR107","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature06246","volume":"449","author":"R Medzhitov","year":"2007","unstructured":"Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 449, 819\u2013826 (2007).","journal-title":"Nature"},{"key":"BFnrmicro2745_CR108","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","volume":"30","author":"H Kumar","year":"2009","unstructured":"Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16\u201334 (2009).","journal-title":"Int. Rev. Immunol."},{"key":"BFnrmicro2745_CR109","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2009.01.004","volume":"21","author":"BN Lambrecht","year":"2009","unstructured":"Lambrecht, B. N., Kool, M., Willart, M. A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23\u201329 (2009).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrmicro2745_CR110","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1749-6632.2010.05787.x","volume":"1213","author":"EF Nicholls","year":"2011","unstructured":"Nicholls, E. F., Madera, L. & Hancock, R. E. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann. NY Acad. Sci. 1213, 46\u201361 (2011).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrmicro2745_CR111","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nri2515","volume":"9","author":"JL Round","year":"2009","unstructured":"Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nature Rev. Immunol. 9, 313\u2013323 (2009).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrmicro2745_CR112","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrmicro2536","volume":"9","author":"BP Willing","year":"2011","unstructured":"Willing, B. P., Russell, S. L. & Finlay, B. B. Shifting the balance: antibiotic effects on host\u2013microbiota mutualism. Nature Rev. Microbiol. 9, 233\u2013243 (2011).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro2745_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrmicro2297","volume":"8","author":"S Lebeer","year":"2010","unstructured":"Lebeer, S., Vanderleyden, J. & De Keersmaecker, S. C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Rev. Microbiol. 8, 171\u2013184 (2010). Three reviews (references 111\u2013113) that cover the recent developments in our understanding of the host interactions with the gut microbiota and the roles of these interactions in health and disease.","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro2745_CR114","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1365-2249.2007.03587.x","volume":"151","author":"M Schlee","year":"2008","unstructured":"Schlee, M. et al. Probiotic lactobacilli and VSL#3 induce enterocyte \u03b2-defensin 2. Clin. Exp. Immunol. 151, 528\u2013535 (2008).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrmicro2745_CR115","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1128\/IAI.01563-06","volume":"75","author":"M Schlee","year":"2007","unstructured":"Schlee, M. et al. Induction of human \u03b2-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 75, 2399\u20132407 (2007).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR116","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1128\/IAI.00188-08","volume":"76","author":"C Cosseau","year":"2008","unstructured":"Cosseau, C. et al. The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect. Immun. 76, 4163\u20134175 (2008).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR117","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/IAI.00040-09","volume":"77","author":"M Hafez","year":"2009","unstructured":"Hafez, M. et al. The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect. Immun. 77, 2995\u20133003 (2009).","journal-title":"Infect. Immun."},{"key":"BFnrmicro2745_CR118","first-page":"CD006289","volume":"4","author":"AC Senok","year":"2009","unstructured":"Senok, A. C., Verstraelen, H., Temmerman, M. & Botta, G. A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. 4, CD006289 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrmicro2745_CR119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-263X.2007.00885.x","volume":"18","author":"S Twetman","year":"2008","unstructured":"Twetman, S. & Stecksen-Blicks, C. Probiotics and oral health effects in children. Int. J. Paediatr. Dent. 18, 3\u201310 (2008).","journal-title":"Int. J. Paediatr. Dent."},{"key":"BFnrmicro2745_CR120","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrmicro1840","volume":"6","author":"JM Wells","year":"2008","unstructured":"Wells, J. M. & Mercenier, A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature Rev. Microbiol. 6, 349\u2013362 (2008).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro2745_CR121","first-page":"467","volume":"8","author":"A Gaspari","year":"2009","unstructured":"Gaspari, A., Tyring, S. K. & Rosen, T. Beyond a decade of 5% imiquimod topical therapy. J. Drugs Dermatol. 8, 467\u2013474 (2009). A recent summary of the applications of the TLR7 agonist imiquimod, one of the most widely used TLR agonists in the clinic.","journal-title":"J. Drugs Dermatol."},{"key":"BFnrmicro2745_CR122","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247\u20131255 (2006). A report detailing the successful clinical trials of a human papilloma virus vaccine that uses an adjuvant formulation, including the TLR4 agonist MPL.","journal-title":"Lancet"},{"key":"BFnrmicro2745_CR123","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","volume":"22","author":"TW Dubensky Jr","year":"2010","unstructured":"Dubensky, T. W. Jr & Reed, S. G. Adjuvants for cancer vaccines. Semin. Immunol. 22, 155\u2013161 (2010).","journal-title":"Semin. Immunol."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrmicro2745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrmicro2745","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrmicro2745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:00:36Z","timestamp":1713693636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrmicro2745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,16]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFnrmicro2745"],"URL":"https:\/\/doi.org\/10.1038\/nrmicro2745","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,16]]}}}